Information Provided By:
Fly News Breaks for February 22, 2019
BEAT
Feb 22, 2019 | 08:29 EDT
BioTelemetry "executed beautifully on all fronts" in Q4 and during 2018 and its outlook for 2019 is strong, Lake Street analyst Brooks O'Neil tells investors in a post-earnings research note. The analyst believes remote patient monitoring is in its infancy and that BioTelemetry is the leader in this "exciting space." He affirms his Buy rating on the shares with a $90 price target.
News For BEAT From the Last 2 Days
There are no results for your query BEAT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.